Organigram

Organigram significantly boosts its cannabis genetics pipeline with a $3 million investment in Phylos Bioscience, extending their strategic alliance through 2030. This partnership grants Organigram priority access to Phylos’ advanced autoflower genetics and exclusive international rights for select cultivars. This move aims to enhance innovation, operational security, and market leadership through seed-based cultivation, ensuring a consistent supply of next-generation genetics for both recreational and medical markets.